GSK plc 6-K, filed Mar 24, 2025
GSK plc (GSK)
6-K
2025-03-24
For: 2025-03-24
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on March 24, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
(the 'Company')
Publication of Notice of Annual General Meeting 2025
The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the
Notice of Annual General Meeting ('AGM') 2025 (the '2025 AGM
Notice'), which will be distributed to shareholders
shortly.
The Company's AGM will be held on Wednesday 7 May 2025 at 2.30pm at
The Landmark London, 222 Marylebone Road, London, NW1 6JQ and will
also be broadcast live for shareholders to join
electronically. Full details of how to join the
meeting either in person or electronically are contained in the
2025 AGM Notice and AGM Guide.
In compliance with Listing Rule 6.4.1R of the UK Financial Conduct
Authority's ('FCA') Listing Rules, the following documents
will be submitted to the FCA and will, in due course, be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism :
●
2025 AGM
Notice
●
Proxy Form for the
AGM
●
The rules of the GSK Share Value
Plan
V A Whyte
Company Secretary
24 March 2025
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
24, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|